ClinicalTrials.gg
CompletedNCT03920852Updated Feb 17, 2020

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

A Phase 1 interventional study of Ruxolitinib cream in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 10 sites in 2 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-02-17.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
13th of 15
41 · median 77
Started
2019
the only one that year
Phase 1
3 of 15
none open now
Registered
5th of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 13th largest by enrollment, is the only one that started in 2019, is one of 3 in phase 1, and was the 5th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is an open-label maximum use trial to evaluate ruxolitinib safety and blood levels after its topical application twice daily to affected areas (≥ 25% BSA) in adolescent and adult participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse events.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic dermatitis
  • ruxolitinib cream
  • maximum use
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with atopic dermatitis as defined by Hanifin and Rajka criteria.
  • Atopic dermatitis duration of at least 2 years.
  • Investigator's Global Assessment score of at least 2 at screening and baseline.
  • Body surface area of atopic dermatitis involvement of ≥ 25% at screening and baseline.
  • Agree to discontinue all agents used to treat atopic dermatitis from screening through the final follow up visit.
  • Willing to take appropriate measures to avoid pregnancy or fathering a child for the duration of study participation with the exception of females of nonchildbearing potential and prepubescent adolescents.
  • Written of the participant or parent(s)/legal guardian and a verbal or written assent from the participant when possible.

Exclusion criteria

Exclusion Criteria:

  • Unstable course of atopic dermatitis (spontaneously improving or rapidly deteriorating) as determined by the investigator over the previous 4 weeks before baseline.
  • Concurrent conditions and history of other diseases:

    • (eg, lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich syndrome).
    • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 14 days (2 weeks) before the baseline visit.
    • Active acute bacterial, fungal, or viral (eg, herpes simplex, herpes zoster, chicken pox) skin infection within 7 days (1 week) before the baseline visit.
    • Any other concomitant skin disorder (eg, generalized erythroderma, such as Netherton syndrome, or psoriasis), pigmentation, or extensive scarring that in the opinion of the investigator may interfere with the evaluation of AD lesions or compromise participant safety.
    • Other types of eczema.
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full study participation, pose a significant risk to the participant, or interfere with interpretation of study data.
  • Use of any of the following treatments within the indicated before baseline:

    • 5 half-lives or 84 days (12 weeks), whichever is longer: biologic agents (eg, dupilumab).
    • 28 days (4 weeks): systemic or adrenocorticotropic hormone analogues, cyclosporine, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (eg, mycophenolate or tacrolimus).
    • 14 days (2 weeks) or 5 half-lives, whichever is longer: immunizations and sedating antihistamines, unless on long-term stable regimen (nonsedating antihistamines are permitted); and potent systemic inhibitors or fluconazole.
    • 7 days (1 week): other topical treatments applied onto atopic dermatitis skin lesions (other than bland emollients), such as corticosteroids, crisaborole, calcineurin inhibitors, coal tar (shampoo), antibiotics, antibacterial cleansing body wash/soap.
  • Treatment with Janus kinase inhibitors (systemic or topical) within 12 weeks (3 months) from baseline.
  • Ultraviolet light therapy or prolonged exposure to natural or artificial sources of ultraviolet radiation (eg, sunlight or tanning booth) within 14 days (2 weeks) before baseline and/or intention to have such exposure during the study, which is thought by the investigator to potentially impact the participant's atopic dermatitis.
  • Positive serology test results at screening for antibody.
  • Liver function test results outside the protocol-defined range.
  • Pregnant or lactating participants or those considering pregnancy.
  • History of alcoholism or drug addiction within 365 days (1 year) before screening or current alcohol or drug use that, in the opinion of the investigator, will interfere with the participant's ability to comply with the administration schedule and study assessments.
  • Current treatment or treatment within 28 days (4 weeks) or 5 half-lives (whichever is longer) before the baseline visit with another medication or current enrollment in another investigational drug protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Ruxolitinib cream

    Drug: Ruxolitinib cream

Interventions

  • Ruxolitinib 1.5% cream applied twice daily.

    Also known as: INCB018424 phosphate cream

06

What researchers measure

Primary outcomes

  1. Number of treatment-emergent adverse events

    Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first application of study drug.

    Time frame: Up to 127 days

Secondary outcomes

  1. Plasma concentration of ruxolitinib

    Time frame: Up to 127 days

  2. Cmax of ruxolitinib

    Maximum measured plasma concentration.

    Time frame: Up to 127 days

  3. Tmax of ruxolitinib

    Time to achieve the observed maximum plasma concentration.

    Time frame: Up to 127 days

  4. AUC0-12 of ruxolitinib

    Area under the concentration-time curve from 0 to 12 hours.

    Time frame: Up to 127 days

07

Study locations

10 sites
  • Orange County Research Center
    Anaheim, California 92801, United States
  • Encino Research Center
    Encino, California 91436, United States
  • San Marcus Research Clinic, Inc.
    Miami Lakes, Florida 33014, United States
  • RM Medical Research, INC.
    Miami, Florida 33174, United States
  • Pure Skin Dermatology Aesthetics at Accel Research
    Orlando, Florida 32819, United States
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • Oakland Hills Dermatology PC
    Auburn Hills, Michigan 48326, United States
  • Clinical Research Institute of Southern Oregon - Crisor
    Medford, Oregon 97504, United States
  • Clinical Research Partners LLC
    Richmond, Virginia 23220, United States
  • Innovaderm Research Inc.
    Montréal, Quebec H2K 4L5, Canada
08

References and documents

Publications

  • Bissonnette R, Call RS, Raoof T, Zhu Z, Yeleswaram S, Gong X, Lee M. A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis. Am J Clin Dermatol. 2022 May;23(3):355-364. doi: 10.1007/s40257-022-00690-3. Epub 2022 Apr 4. PubMed 35368221 ↗
  • Scuron MD, Fay BL, Connell AJ, Peel MT, Smith PA. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis. Front Immunol. 2021 Feb 15;11:620098. doi: 10.3389/fimmu.2020.620098. eCollection 2020. PubMed 33658996 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Dec 2019, 6 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 6 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
Apr 19, 2019
StartActual
May 30, 2019
Primary completionActual
Dec 26, 2019
CompletionActual
Dec 26, 2019
Last update
Feb 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03920852
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 19, 2019
Start date
May 30, 2019
Primary completion
Dec 26, 2019
Completion
Dec 26, 2019
Last update
Feb 17, 2020

Study contacts

Michael E. Kuligowski, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion